23andMe Holding Co. Class A Common Stock (ME) News

23andMe Holding Co. Class A Common Stock (ME): $2.08

0.04 (+1.96%)

POWR Rating

Component Grades













Filter ME News Items

ME News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ME News Highlights

  • ME's 30 day story count now stands at 9.
  • Over the past 27 days, the trend for ME's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • LI, DNA and GSK are the most mentioned tickers in articles about ME.

Latest ME News From Around the Web

Below are the latest news stories about 23ANDME HOLDING CO that investors may wish to consider to help them evaluate ME as an investment opportunity.

23andMe Q4 2023 Earnings Preview

  • 23andMe (NASDAQ:ME) is scheduled to announce Q4 earnings results on Thursday, May 25th, after market close.

Seeking Alpha | May 24, 2023

Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.

Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities.

Faizan Farooque on InvestorPlace | May 19, 2023

Here's Why We're Not Too Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | May 16, 2023

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said they had personally taken a direct-to-consumer genetic health test SUNNYVALE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with

Yahoo | May 16, 2023

3 Personalized Medicine Stocks to Buy for Long-Time Returns

Personalized medicine is the future of medicine.

John Blankenhorn on InvestorPlace | May 15, 2023

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on Thursday, May 25, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress. The webcast

Yahoo | May 11, 2023

23andMe Releases New Report Revealing Likelihood of Developing Lupus

23andMe+ members can now gain insights on the chronic autoimmune conditionSOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the skin, joints, heart, lungs, kidneys, circulating blood cells, or brain. The report, which is powered by data from c

Yahoo | May 9, 2023

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategySOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheadin

Yahoo | May 8, 2023

Why the human genome could be health care’s holy grail

23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once ...

Yahoo | May 2, 2023

23andMe CEO: We see more opportunities in DNA partnerships

23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.

Yahoo | May 1, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6539 seconds.